Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 5
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more

Conditions: Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
Interventions: Ezetimibe; Drug
Lead sponsor: Richard E. Ostlund Jr., MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure, Hypertension, Diabetes Mellitus, Stroke, BPH, Hyperlipidemia
Interventions: Virtual Visit; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension in Pregnancy
Interventions: Remote (text based) surveillance; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Retinopathy
Interventions: Runcaciguat (BAY1101042), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Thoracoabdominal Aortic Aneurysm, Thoracoabdominal; Aortic, Aneurysm, Dissecting, Pararenal Aneurysm, Frailty Syndrome
Interventions: Physician Modified Endografts; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Peer Led, Seminar; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Sturge-Weber Syndrome
Interventions: Cannabidiol; Drug
Lead sponsor: Anne Comi, MD; Other
Eligibility: 1 Month to 45 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myocardial Infarction, Hypertension, Stroke
Interventions: BP REACH Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 35 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Downey, California • Los Angeles, California • Sylmar, California + 1 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more

Conditions: Stroke
Interventions: Robotic exoskeleton for walking assist; Device
Lead sponsor: College of St. Scholastica, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Carotid Artery Plaque
Interventions: Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination; Combination Product · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: epoetin alfa; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myocardial Bridging
Interventions: Nebivolol, Diltiazem, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
Interventions: Standard of Care, Revita, Relese, Cogenex, Enverse; Other
Lead sponsor: StimLabs; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more

Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more

Conditions: Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elranatamab, GM-CSF, DC/MM Fusion Vaccine; Drug · Biological
Lead sponsor: David Avigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cerebral Vascular Accident
Interventions: CO-OP Group; Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plasma Cell Myeloma, Residual Disease
Interventions: Ixazomib Citrate, Lenalidomide, Dexamethasone; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hemodynamics, Renal Dialysis, Sepsis, Shock
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 25
States / cities: Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more

Search by objective public record fields.

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Physiological Study of Human Cholesterol Metabolism and Excretion

Virtual Visits at Brigham and Women's Hospital

Remote Surveillance of Postpartum Hypertension

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Health Evaluation in African Americans Using RAS Therapy

Frailty and Physician Modified Fenestrated Endograft for Thoracoabdominal Aortic Pathologies

Working With Veterans Organizations to Improve Blood Pressure

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Reducing Blood Pressure in Patients With High Cardiovascular Risk

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Post Stroke Walking Kinematics Using the Honda Walking Assist Robotic Exoskeleton

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Implementing a CO-OP Group in the Day Rehab Setting: A Pilot Study.

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Presep and Vascath Interaction Study

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])